Holen Sie sich die Stockscreener-App
3.54
0.00%
0.00
Schlusskurs vom Vortag:
$3.54
Offen:
$3.54
24-Stunden-Volumen:
3,651
Relative Volume:
0.01
Marktkapitalisierung:
$2.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.73M
KGV:
-0.0105
EPS:
-335.7162
Netto-Cashflow:
$-14.29M
1W Leistung:
+0.85%
1M Leistung:
-17.10%
6M Leistung:
+78.79%
1J Leistung:
-66.11%
1-Tages-Spanne:
$3.51
$3.57
1-Wochen-Bereich:
$3.37
$3.65
52-Wochen-Spanne:
$0.4229
$55.00
Genprex Inc Stock (GNPX) Company Profile
Firmenname
Genprex Inc
Sektor
Branche
Telefon
512-537-7997
Adresse
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
3.54 | 2.90M | 0 | -16.73M | -14.29M | -335.72 |
VRTX
Vertex Pharmaceuticals Inc
|
522.04 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
799.73 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.06 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.54 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.27 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-01-26 | Eingeleitet | National Securities | Buy |
| 2019-04-29 | Eingeleitet | Noble Capital Markets | Outperform |
Genprex Inc Aktie (GNPX) Neueste Nachrichten
Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
Genprex Stock Price Forecast. Should You Buy GNPX? - StockInvest.us
Genprex Selects Andelyn Biosciences to Scale Manufacturing for Diabetes Gene Therapy Program - Contract Pharma
Andelyn Biosciences Secures Manufacturing Role in Genprex Diabetes Gene Therapy Program - TipRanks
Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program | Newswise - Newswise
Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program - PR Newswire
Genprex Inc. (GNPX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Genprex signs CDMO deal to scale up diabetes gene therapy manufacturing - Minichart
Form 8K Genprex Inc For: 18 August By Investing.com - Investing.com Nigeria
Genprex partners with CDMO for diabetes gene therapy manufacturing By Investing.com - Investing.com Nigeria
Genprex (GNPX) Partners with CDMO to Advance Diabetes Gene Thera - GuruFocus
Genprex partners with CDMO for diabetes gene therapy manufacturing - Investing.com
GenprexTransfers Diabetes Product Manufact - Moomoo
Genprex advances AAV diabetes gene therapy manufacturing - TipRanks
Genpre announces CDMO partnership to scale AAV diabetes gene therapy toward cGMP clinical supply - TradingView
Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy - PR Newswire
GNPX Q1 2026 Earnings: Clinical-Stage Biotech Posts $0.64 Per Share Loss as Pipeline Development ContinuesGuidance Update - vinanet.vn
Genprex, Inc. Q2 2026: Net loss $(4.45M), EPS $(9.40) — 10-Q Summary - TradingView
Genprex (NASDAQ: GNPX) details Q2 loss and cash runway into 2027 - Stock Titan
Genprex Inc (GNPX) Debt 2025 - Stock Titan
Genprex (GNPX) Surges 5% on Renewed Biotech Interest — Key Levels to WatchShort Setup Alerts - vinanet.vn
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer (PR Newswire) - Aktiellt
Genprex Inc (STU:2DE1) Stock Earnings Transcripts - GuruFocus
Genprex Inc (STU:2DE1) Stock Price & 30 Year Financial Data - GuruFocus
Genprex Inc (GNPX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Genprex Inc (GNPX) Stock News Today - TradingKey
Genprex (GNPX) Q1 2026 Earnings: Net Loss of $0.64 Per Share Highlights Pre-Revenue Clinical Development Stage - dars.gov.et
Genprex Regains Nasdaq Compliance, Listing Status Secured - The Globe and Mail
Genprex, Inc. (NASDAQ: GNPX) regains Nasdaq minimum bid compliance - Stock Titan
Genprex partners with Roche Diagnostics on biomarker validation for NSCLC - Yahoo Finance
Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies - Morningstar
Genprex, Roche Partner on NSCLC Biomarker Validation - TipRanks
Genprex Shares Rise After Collaboration With Roche Diagnostics - finance.yahoo.com
GNPX Stock Draws Trader Focus After Wild Price Swing - StocksToTrade
Why is Genprex stock sliding today? By Investing.com - Investing.com Canada
Weekly Recap: Nasdaq exception and Roche Diagnostics TROP2 validation - TradingView
Genprex stock rises on Roche Diagnostics collaboration By Investing.com - Investing.com India
Genprex partners with Roche on lung cancer biomarker studies - Investing.com Nigeria
Genprex partners with Roche on lung cancer biomarker studies By Investing.com - Investing.com Canada
GNPX Stock Slides After Parabolic Spike Draws Trader Scrutiny - StocksToTrade
Genprex Granted Nasdaq Listing Exception Amid Compliance Push - The Globe and Mail
Genprex Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Genprex Inc (GNPX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Genprex Inc (GNPX) Institutional Confidence - TradingKey
Genprex Inc (GNPX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Genprex Inc (GNPX) Earnings Date & Reports & Earnings News - TradingKey
Genprex Inc (GNPX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Genprex Inc (GNPX) Valuation: PE, PB & Fair Value Analysis - TradingKey
GNPX|Genprex Inc|Price:3.950|Chg%:-0.040 - TradingKey
TradingKey - TradingKey
GNPX|Genprex Inc|Price:7.735|Chg%:-0.075 - TradingKey
Finanzdaten der Genprex Inc-Aktie (GNPX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):